

6 JUNE 2003



Medical

**NERVE AGENT ANTIDOTES AND
PRETREATMENT TABLETS ISSUE**

COMPLIANCE WITH THIS PUBLICATION IS MANDATORY

NOTICE: This publication is available digitally on the AFDPO WWW site at:
<http://www.e-publishing.af.mil>

OPR: 911 ASTS/SGA (MSgt L. Hughson)

Certified by: 911 AW/CC (Col Carl E. Vogt)

Pages: 2

Distribution: F

This instruction implements Air Force Policy Directive 44-1, *Medical Operations*. It establishes procedures for ensuring that nerve agent antidotes and pretreatment tablets (p-tabs) are issued to individuals deploying to areas of a possible chemical warfare agent threat in accordance with AFMAN 23-110 Volume 5, *USAF Supply Manuals*.

1. Responsibilities:

1.1. 911 Airlift Wing/XP will:

1.1.1. Notify 911 ASTS/SGA upon notification of contingency operations requiring nerve agent antidotes and pretreatment tablets (p-tabs).

1.2. Unit Deployment Manager will:

1.2.1. Notify 911 ASTS/SGA of the number of individuals processing by exception. Primary aircrew members and Mission Essential Ground Personnel (MEGP) may process by exception (individuals not processing through the PAX terminal or the mobility processing line).

1.2.2. Procure from 911 ASTS/SGA nerve agent antidotes and p-tabs for individuals processing by exception and ensure their security under lock and key, until issued to deploying individuals.

1.3. 911 ASTS/SGA will:

1.3.1. Obtain approval from Installation deployment Officer (IDO) for approval to issue Pyridostigmine Bromide (p-tabs).

1.3.2. Notify 74th Medical Group/SGSL; Wright-Patterson AFB, OH; Medical War Readiness Materials (MWRM) warehouse, of the requirement for nerve agent antidotes and p-tabs and total number of individuals deploying.

1.3.3. Procure and pick-up from the MWRM the nerve agent antidotes and p-tabs within 24 hours.

- 1.3.4. Issue nerve agent antidotes and p-tabs at PAX terminal or Mobility Processing Line to individuals deploying on day of actual deployment.
- 1.3.5. Ensure security of nerve agent antidotes and p-tabs prior to issuing to individuals deploying.
- 1.3.6. Collect unused nerve agent antidotes and p-tabs upon return from contingency operations at PAX terminal.
- 1.4. 911 ASTS/SGSL will:
 - 1.4.1. Provide nerve agent antidotes and p-tabs as required by notification from 911 MDS/SGA.
- 1.5. 911 ASTS/SGPM will:
 - 1.5.1. Brief each individual deploying on the use and precautions of the nerve agent antidotes and p-tabs during the medical intelligence briefing prior to deploying.

2. Requirements:

- 2.1. Nerve Agent Antidote Kit, MARK 1, 3 sets:
 - 2.1.1. Atropine auto injector.
 - 2.1.2. 2 PAM Cl auto injector.
 - 2.1.3. Plastic clip.
 - 2.1.4. Foam carrying case.
- 2.2. Diazepam, CANA, 1 auto injector.
- 2.3. Nerve Agent Pyridostigime Treatment Tablet Set:
 - 2.3.1. Pyridostigmine Bromide, 30 mg, 21 tablet, blister pack.
- 2.4. During exercise scenarios the nerve agent antidotes will be simulated:
 - 2.4.1. Atropine auto injector - plain colored clothes pin.
 - 2.4.2. 2 PAM Cl - yellow clothespin.
 - 2.4.3. Diazepam - tongue depressor.
 - 2.4.4. P-tabs - cardboard punch out card.

CARL E. VOGT, Colonel, USAFR
Commander